My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

68.14 -2.58 (-3.65%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Why Is BridgeBio Pharma (BBIO) Stock Up 60% Today? ↗

March 06, 2023

BBIO stock looks unstoppable today as BridgeBio Pharma diligently advances a treatment for a rare and unfortunate condition.

Via InvestorPlace

BridgeBio's Dwarfism Candidate Shows Favorable Height Increase, Safety Profile ↗

March 06, 2023

BridgeBio Pharma Inc (NASDAQ: BBIO) announced results from PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia, a genetic condition affecting a protein in the body called the...

Via Benzinga

What's Going On With Kala Pharmaceuticals Shares Today ↗

March 06, 2023

Kala Pharmaceutical (NASDAQ: KALA) shares skyrocketed more than 20% Monday morning on higher-than-average volume. On an average market day, Kala shares trade about 2.5 million times throughout the...

Via Benzinga

Kennedy-Wilson, Radian Group, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗

March 06, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

What's Going On With Avalon GloboCare Shares Today ↗

March 06, 2023

The overall market ticked slightly higher in pre-market trading Monday morning, but Avalon Globocare Corp (NASDAQ: ALBT) shares really took off. Avalon GloboCare is a biotech company headquartered in...

Via Benzinga

Looking Into BridgeBio Pharma's Return On Capital Employed ↗

February 28, 2023

Via Benzinga

Looking Into BridgeBio Pharma's Return On Capital Employed ↗

November 23, 2022

Via Benzinga

BridgeBio Pharma: Q3 Earnings Insights ↗

November 03, 2022

BridgeBio Pharma (NASDAQ:BBIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January ↗

March 06, 2023

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 33,471.14 while the NASDAQ rose...

Via Benzinga

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study ↗

March 06, 2023

The company is testing a drug for children with achondroplasia, a cause of dwarfism.

Via Investor's Business Daily

Why BridgeBio Pharma Stock Is Hitting New 52-Week Highs Monday ↗

March 06, 2023

BridgeBio Pharma Inc (NASDAQ: BBIO) shares are ripping higher Monday morning after the company announced positive data for its phase 2 study of

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 06, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 16, 2023

Via Benzinga

BridgeBio Pharma Shares Preliminary Data From Gene Therapy Candidate In Ultra Rare Disorder ↗

October 14, 2022

Via Benzinga

LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial ↗

October 13, 2022

Via Benzinga

BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial ↗

August 18, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023 ↗

February 06, 2023

Via Benzinga

Why BridgeBio Pharma Stock Is Shooting Higher ↗

December 29, 2022

BridgeBio Pharma Inc (NASDAQ: BBIO) shares are trading higher by 16.77% to $7.87 Thursday afternoon after the company initiated its CALIBRATE Phase 3 study of Encaleret. What Else?

Via Benzinga

BridgeBio Pharma Earnings Perspective: Return On Capital Employed ↗

August 25, 2022

According to Benzinga Pro data, during Q2, BridgeBio Pharma (NASDAQ:BBIO) posted sales of $73.75 million. Earnings were up 98.73%, but BridgeBio Pharma still reported an overall loss of $2.56 million.

Via Benzinga

BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate ↗

July 26, 2022

Via Benzinga

Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session ↗

December 29, 2022

Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 25, 2022

Via Benzinga

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 18, 2022

Via Benzinga

Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.

Via Benzinga

BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off ↗

August 18, 2022

BridgeBio Pharma (NASDAQ: BBIO) has dosed first patient in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by...

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 10, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 03, 2022

Via Benzinga

Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday ↗

July 27, 2022

Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary ↗

July 26, 2022

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.